SGMT: Denifanstat's phase III acne trial launches soon, aiming for rapid market entry and long exclusivity
Denifanstat, a novel oral FASN inhibitor, is advancing to a US phase III acne trial with strong efficacy and safety data, targeting a large unmet need. Premium pricing and broad payer support are anticipated, with patent protection extending to 2037 and a second-generation molecule in development.B…
Story updates
07:51:08 PM UTC
SquawkNews
Denifanstat, a novel FASN inhibitor, is advancing rapidly with strong phase III data in acne and MASH, a favorable safety profile, and FDA support for a single pivotal US trial including adolescents. Commercial plans target premium pricing, broad payer coverage, and a flexible launch strategy.Based…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.